Duplex sequencing (Duplex Seq) has an ultra-low error rate, allowing for direct detection of rare mutations. TwinStrand Biosciences, Inc., has created a DuplexSeq Human-50 Mutagenesis Assay, which uses a bait-and-capture approach to sample 20 genic and intergenic target sites throughout the genome (covering approximately 50kb), that can potentially overcome certain guideline in vitro assay limitations. Inotiv currently uses this technology as presented at the Genetic Toxicology Association Meeting and highlights a study conducted under our contract supporting the National Toxicology Program.
Download your copy of the presentation to learn more about DuplexSeq technology in use at Inotiv, including
• Detection of rare mutations that aren’t detected by traditional in vitro genetox assays
• Robust reproducibility between different labs
• Optimized sampling times of TK6 Cells to detect mutational events
